BioCryst Pharmaceuticals is trading 5.63% up now at $10.50, with continued buying potentially supported by its August 5 earnings report.
- The report showed stronger-than-expected second-quarter results, raised full-year revenue guidance, and lower operating-cost guidance.
- No fresh company-specific announcement dated August 18, 2026 was identified; the immediate catalyst remains unconfirmed.
- The broader pre-market tape is weaker, with the Nasdaq down 1.09%.